Director Treco James buys 250 TNXP shares at $36.00; stock down 20.1% in 30 days, trading -41.4% from 52-week high
Treco James purchased 250 shares at $36.00, establishing an initial position in Tonix Pharmaceuticals, which is currently unprofitable with net income of $-28.3M against quarterly revenue of $2.0M. The stock has declined 20.1% over the past 30 days and is substantially below its 52-week high of $61.57, trading at $36.05 currently—the purchase price is at the low end of recent activity. Despite recent weakness, the company has posted annual revenue growth of 29.9%, suggesting underlying business momentum. The modest transaction size ($9.0K) and founder's first-time accumulation merit monitoring to see whether this initial purchase signals broader conviction or is an exploratory position in a volatile, loss-making biotech.